IMNM — Immunome, Inc. stock price, charts and financials

Latest market price

23.01

+0.25+1.10%

Overview Short InterestFilings

IMNMQT72Immunome, Inc.·NASDAQ

Overview Short InterestFilings

23.01+1.10%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

KLRA+2.24%$17.32 NUVB-2.69%$6.16 SION+4.52%$49.26 PGEN+5.42%$6.61 MLYS+1.02%$25.78 AMLX-0.69%$20.17 PHVS-1.13%$32.25 BCRX-1.89%$8.81

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.08	Insider Own	8.63%	Shs Outstand	95.60M	Perf Week	2.48%

Market Cap	2.18B	Forward P/E	-	EPS next Y	-2.18	Insider Trans	-7.02%	Shs Float	79.25M	Perf Month	5.91%

Enterprise Value	1.60B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	21.75%	Perf Quarter	-0.78%

Income	-189.73M	P/S	-	EPS this Y	30.43%	Inst Trans	-	Short Ratio	12.88	Perf Half Y	-9.21%

Sales	4.01M	P/B	4.37	EPS next Y	-1.74%	ROA	-36.24%	Short Interest	17.24M	Perf YTD	5.96%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-51.15%	52W High	27.96 -17.69%	Perf Year	111.72%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-40.31%	52W Low	8.76 162.82%	Perf 3Y	207.57%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	-1161.92%	Volatility	4.70% 5.23%	Perf 5Y	33.73%

Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	38.40%	Oper. Margin	-5947.90%	ATR (14)	1.11	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	21.68	Sales Y/Y TTM	44.44%	Profit Margin	-5593.85%	RSI (14)	54.59	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	21.68	EPS Q/Q	7.69%	SMA20	-0.92%	Beta	2.04	Target Price	36.50

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-100.00%	SMA50	7.13%	Rel Volume	0.49	Prev Close	22.76

Employees	177	LT Debt/Eq	0.01	Earnings	Aug 05	SMA200	8.58%	Avg Volume	1.33M	Price	23.01

IPO Date	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.69% -	Net Debt/EBITDA	2.61	Volume	658,123	Change	1.10%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-28-26	Reiterated	Barclays		$36
May-28-26	Reiterated	Truist Securities	Buy	$36 → $37
May-15-26	Reiterated	Leerink Partners	Outperform	$40 → $33
Feb-12-26	Initiated	H.C	Buy	$40
Dec-16-25	Reiterated	Lake Street	Buy	$32
Dec-16-25	Reiterated	Evercore ISI Group	Outperform	$18 → $40
Dec-15-25	Reiterated	Leerink Partners		$38 → $40
Dec-01-25	Initiated	Truist	Buy	$36
Nov-17-25	Reiterated	Stephens & Co.	Overweight	$33
Sep-05-25	Initiated	Craig-Hallum	Buy	$26

Latest News

Jul-24-26

Jul-24-2603:58AM

Atika Capital Management LLC Sells 71,441 Shares of Immunome, Inc. $IMNMdefenseworld.net

Jul-21-26

Jul-21-2609:33AM

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price TargetBenzinga

Jul-20-26

Jul-20-2607:30AM

Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumorsbusinesswire.com

Jul-12-26

Jul-12-2604:44PM

What This Immunome Sale Means a Day Before a Big FDA Milestonefool.com

Jul-10-26

Jul-10-2611:41AM

Immunome Stock Up 32% in a Month: Here's What You Should Knowzacks.com

Jul-08-26

Jul-08-2601:18PM

Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA ReviewBenzinga

07:30AM

Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumorsbusinesswire.com

Jul-07-26

Jul-07-2604:02PM

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com

Jun-12-26

Jun-12-2610:04AM

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price TargetBenzinga

Jun-11-26

Jun-11-2607:32AM

Immunome Does First Participant In Its Phase 1 IM-1617 Study To Treat Solid TumorsBenzinga

Company

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	13	7	9	14	0	0	0	0	0
Cost of Goods Sold Incl. D&A	1	3	0	0	0	0	1	1	1
Gross Profit	12	4	9	14	0	0	-1	-1	-1
Selling, General and Administrative Excl. Other	41	44	33	20	14	11	5	2	1
Research and Development	162	174	130	23	23	14	7	9	7
Other Operating Expense	34	0	152	81	0	0	0	-1	0
Operating Income	-225	-214	-306	-110	-37	-25	-12	-10	-8
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	2	13	3	0	1	-6	0	0
Net Income Before Taxes	-212	-212	-293	-107	-37	-25	-18	-10	-8
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-212	-212	-293	-107	-37	-25	-18	-11	-8
Net Income From Continuing Operations	-212	-212	-293	-107	-37	-25	-18	-10	-8
Net Income	-212	-212	-293	-107	-37	-25	-18	-11	-8
EPS (Recurring)	-3.08	-2.43	-5.00	-5.38	-3.09	-2.14	-1.69	-1.84	-7.18
EPS (Basic, Before Extraordinaries)	-3.08	-2.43	-5.00	-5.38	-3.09	-2.14	-1.69	-1.84	-7.18
EPS (Diluted)	-3.08	-2.43	-5.00	-5.38	-3.09	-2.14	-1.69	-1.84	-7.18
EBITDA	-182	-209	-151	-28	-36	-24	-17	-10	-7
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	153.99	266.97	69.62	15.29	—	—	—	—	—
Gross Margin	92.31	57.14	100.00	100.00	—	—	—	—	—
Operating Margin	-1,730.77	-3,057.14	-3,400.00	-785.71	—	—	—	—	—
Net Margin	-1,630.77	-3,028.57	-3,255.56	-764.29	—	—	—	—	—
Shares Outstanding	87	87	59	20	12	12	10	6	1
Market Capitalization	2,002	1,869	627	214	27	156	97	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Kinney	CHIEF BUSINESS OFFICER	Jul 07 '26	Sale	25.00	1,092	27,300	0	Jul 09
Horn Kinney	CHIEF BUSINESS OFFICER	Jul 07 '26	Option Exercise	12.92	1,092	14,109	1,092	Jul 09
Barchas Isaac	Director	Jul 07 '26	Sale	24.20	16,906	409,125	108,504	Jul 07
Barchas Isaac	Director	Jul 06 '26	Sale	24.11	83,094	2,003,396	125,410	Jul 07
Lechleider Robert	Chief Medical Officer	Jul 02 '26	Sale	22.62	55,000	1,244,331	15,805	Jul 07
Lechleider Robert	Chief Medical Officer	Jul 02 '26	Option Exercise	8.73	55,000	480,150	70,805	Jul 07
Barchas Isaac	Director	Jul 02 '26	Sale	22.59	100,000	2,258,849	208,504	Jul 02
Barchas Isaac	Director	Jun 30 '26	Sale	21.12	101,050	2,134,176	308,504	Jul 02
Lechleider Robert	Chief Medical Officer	Jun 25 '26	Option Exercise	8.73	55,000	480,150	70,805	Jun 29
Lechleider Robert	Chief Medical Officer	Jun 25 '26	Sale	19.85	55,000	1,091,662	15,805	Jun 29
Rosett Max	Chief Financial Officer	Jun 15 '26	Option Exercise	1.05	60,000	63,000	114,037	Jun 17
Rosett Max	Chief Financial Officer	Jun 15 '26	Sale	18.23	60,000	1,093,800	54,037	Jun 17
BIENAIME JEAN JACQUES	Director	Jun 05 '26	Buy	19.45	10,500	204,260	43,415	Jun 09
BIENAIME JEAN JACQUES	Director	Jun 05 '26	Sale	19.41	10,500	203,820	32,915	Jun 09
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	20.70	5,000	103,500	43,415	May 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.